Researchers examined problems related to the timing and scheduling of surgeries and patients' stays in recovery units. In ...
The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback